Showing 1 to 2 of 2 results


NHS Resumes UK Blood Plasma Use, Saving Millions and Improving Patient Care
After a 24-year pause due to vCJD fears, the NHS has restarted using UK-donated blood plasma for medicine, saving up to £10 million yearly in import costs and providing life-saving treatment for patients like four-year-old Ruby Harris who received albumin for a serious liver issue.
NHS Resumes UK Blood Plasma Use, Saving Millions and Improving Patient Care
After a 24-year pause due to vCJD fears, the NHS has restarted using UK-donated blood plasma for medicine, saving up to £10 million yearly in import costs and providing life-saving treatment for patients like four-year-old Ruby Harris who received albumin for a serious liver issue.
Progress
48% Bias Score

Takeda's Plasma-Derived Therapies: Challenges and Growth in a Concentrated Market
Takeda's plasma-derived therapies (PDT) business, generating $5.98 billion in 2023 (21% of total revenue), faces challenges due to concentrated plasma sourcing (90% from 5 countries) and increasing global demand projected to reach $46.7 billion by 2031; Takeda is addressing this through process impr...

Takeda's Plasma-Derived Therapies: Challenges and Growth in a Concentrated Market
Takeda's plasma-derived therapies (PDT) business, generating $5.98 billion in 2023 (21% of total revenue), faces challenges due to concentrated plasma sourcing (90% from 5 countries) and increasing global demand projected to reach $46.7 billion by 2031; Takeda is addressing this through process impr...
Progress
24% Bias Score
Showing 1 to 2 of 2 results